KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Accumulated Expenses (2017 - 2025)

Bionano Genomics' Accumulated Expenses history spans 6 years, with the latest figure at $5.6 million for Q4 2024.

  • For Q4 2024, Accumulated Expenses fell 30.26% year-over-year to $5.6 million; the TTM value through Dec 2024 reached $5.6 million, down 30.26%, while the annual FY2024 figure was $5.6 million, 30.26% down from the prior year.
  • Accumulated Expenses for Q4 2024 was $5.6 million at Bionano Genomics, up from $5.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.6 million in Q4 2022 and bottomed at $2.4 million in Q2 2020.
  • The 5-year median for Accumulated Expenses is $5.6 million (2024), against an average of $6.4 million.
  • The largest annual shift saw Accumulated Expenses soared 169.03% in 2021 before it tumbled 30.26% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $5.6 million in 2020, then surged by 53.97% to $8.6 million in 2021, then rose by 22.4% to $10.6 million in 2022, then dropped by 23.34% to $8.1 million in 2023, then crashed by 30.26% to $5.6 million in 2024.
  • Per Business Quant, the three most recent readings for BNGO's Accumulated Expenses are $5.6 million (Q4 2024), $5.5 million (Q2 2024), and $8.1 million (Q4 2023).